The effect of melatonin supplementation on lead, calcium and magnesium distribution in the tissues of lead-exposed rats

Polish Journal of Environmental Studies

Volumn 17, Issue 2, 2008, Pages 181-188

  Baranowska Bosiacka, Ika ^a   Gutowska, I ^a   Marchlewicz, M ^a   Nocen I ^a   Czuprynska K ^a   Olszewska, M ^a   Skotnicka, E ^b   Jach, M ^a   Wiszniewska, B ^a   Chlubek, D ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF SZCZECIN   (Poland)

Author keywords

Bones; Calcium; Lead; Magnesium; Melatonin supplementation; Teeth

Indexed keywords

RATTUS; RATTUS NORVEGICUS;

EID: 42549084805     PISSN: 12301485     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. GRANDJEAN P., OLSEN N.B. Lead. In: Hazardous Metals in Human Toxicology, Part B.; A. Veromysse (eds.), Elsevier: Amsterdam, 1984.
2. HU H., RABINOWITZ M., SMITH D. Bone lead as biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms. Environ. Health Perspect. 106, 1, 1998.
3. O'FLAHERTY E.J. A physiologically based kinetic model for lead in children and adults. Environ. Health Perspect. 106 (6), 1495, 2000.
4. GWIAZDA R., CAMPBELL C., SMITH D. A non-invasive isotopic approaches to estimate the bone lead in children: implications for assessing the efficacy of lead abatement. Environ. Health Perspect. 113, 104, 2005.
5. FOWLER B.A. Biological roles of high affinity metal-binding proteins in mediating cell injury. Comm. Toxicol. 3, 27, 1989.
6. SIMONS T.J.B. Lead transport and binding by human erythrocytes in vitro. Pfugers Arch. 423, 307, 1993.
7. KOSTIAL K., BLANUSA M., PIASEK M., RESTEK-SAMARZIJA N., JONEM M.M., SIGM P.K. Combined chelation therapy in reducing lead concentrations in suckling rats. J. App. Toxicol. 19, 143, 1999.
8. LISIEWICZ J., MOSZCZYŃSKI P. Industrial Hematology. PZWL: Warsaw, 1999. [In Polish]
9. CANFIELD R.L., HENDERSON C.R., CORY-SLECHTA D.A., COX C., JUSKO T.A., LANPHEAR B.P. Intellectual impairment in children with blood concentrations below 10 μg per decilitre. N. Eng. J. Med. 348, 1517, 2003.
10. DIETRICH K.N., RIS M.D., SUCCOP P.A., BERGER O.G., BORNSCHEIN R.L. Early exposure to lead and juvenile delinquency. Neurotoxicol. Teratol. 32, 511, 2001.
11. NEEDLEMAN H.L., FARLAND C., NESS R.B., FIENBERG S.E., TOBIN M.J. Bone lead levels in adjudicated delinquents: a case-control study. Neurotoxicol. Teratol. 24, 711, 2002.
12. MARCHLEWICZ M., WISZNIEWSKA B., GONET B., BARANOWSKA-BOSIACKAI., SAFRANOW K., KOLASA A., GŁABOWSKI W., KURZAWA R., JAKUBOWSKA K., RAĆ M. Increased lipid peroxidation and ascorbic acid utilization in testis and epididymis of rats chronically exposed to lead. BioMetals 20, 13, 2006.
13. PAL S., CHATTERJEE A.K. Possible beneficial effects of melatonin supplementation on arsenic-induced oxidative stress in Wistar rats. Drug. Chem. Toxicol. 29, 423, 2006.
14. REITER R.J., TAN D.X., QI W., MANCHESTER L.C., KARBOWNIK M., CALVI J.R. Pharmacology and physiology of melatonin in the reduction of oxidative stress in vivo. Biol. Signals Recept. 9, 160, 2000.
15. JOU M.J., PENG T.I., REITER R.J., JOU S.B., WU H.Y., WEN S.T. Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J. Pineal. Res. 37, 55, 2004.
16. KARBOWNIK M., GITTO E., LEWINSKI A., REITER R.J. Introduction of lipid peroxidation in hamster organs by the carcinogen cadmium: amelioration by melatonin. Cell Biol. Toxicol. 17, 33, 2001.
17. REITER R.J., TAN D.X., MANCCHESTER L.C, CALVO J.R. Handbook of antioxidants. Marcel Dekker. New York, pp. 565-613, 2002.
18. SMIRNOV A.N. Nuclear melatonin receptors. Biochemistry (Mosc) 1, 19, 2001.
19. ANTOLIN I., RODRIQUES C., SAINZ R.M., MAYO J.C., URIA H., KOTLER M.L., RODRIQUES-COLUNGA M.J., TOLIVIA D., MENENDEZ-PELAEZ A. Neurohormone melatonin prevents cell damage: effect on gene expression for antioxidant enzymes. FASEB J. 10, 882, 1996.
20. SRINIVASAN V. Melatonin oxidative stress and neurodegenerative diseases. Indian J. Exp. Biol. 40, 668, 2002.
21. SURESH C., DENNIS A.O., HEINZ J., VEMURI M.C., CHETTY C.S. Melatonin protection against lead-induced changes in human neuroblastoma cell cultures. Int J Toxicol. 25, 459, 2006.
22. EL-SOKKARY G.H., ABDEL-RAHMAN G.H., KAMEL E.S. Melatonin protects against lead-induced hepatic and renal toxicity in male rats. Toxicology. 213, 25, 2005.
23. OTHMAN A.I, AL SHARAWY S, EL-MISSIRY M.A. Role of melatonin in ameliorating lead induced haematotoxicity. Pharmacol Res. 50, 301, 2004.
24. FLORA S.J., PANDE M., KANNAN G.M., MEHTA A. Lead induced oxidative stress and its recovery following co-administration of melatonin or N-acetylcysteine during chelation with succimer in male rats. Cell. Mol. Biol. 50, 543, 2004.
25. EL-MISSIRY M.A. Prophylactic effect of melatonin on lead-induced inhibition of heme biosynthesis and deterioration of antioxidant systems in male rats. J. Biochem. Mol. Toxicol. 14, 57, 2000.
26. KIM Y.O., PYO M.Y., KIM J.H. Influence of melatonin on immunotoxicity of lead. Int. J Immunopharmacol. 22, 821, 2000.
27. WESTRLUND-HELMERSON U. Determination of lead and cadmium in blood by modification of the Hassel method. At. Abs. News 9, 133, 1978.
28. CDC (Centers for Disease Control). Preventing lead poisoning in young children. United States Department of Health and Human Services: Department of Health and Human Services: Atlanta, 1991.
29. SEŃCZUK W. Toxicology. PZWL: Warsaw, pp 490-427, 1994. [In Polish]
30. WHO. Environmental Health Criteria 165. Inorganic lead. Geneva, 1995.
31. CDC (Centres for Disease Control). United States Department of Health and Human Services: Atlanta, 2004. http://www.cdc.gov/nceh/lead/ ACCLPP/MeetingMinutes/lessT-han10MtgMAR04.pdf
32. LIDSKY T.I., SCHNEIDER J.S. Lead neurotoxicity in children: basic mechanisms and clinical correlates. Brain 126, 5, 2003.
33. KARBOWNIK M., GITTO E., LEWINSKI A., REITER R.J. Introduction of lipid peroxidation in hamster organs by the carcinogen cadmium: amelioration by melatonin. Cell Biol. Toxicol. 17, 33, 2001.
34. REITER R.J. TAN DX, QI W., MANCHESTER LC, KARBOWNIK M., CALVI J.R., Pharmacology and physiology of melatonin in the reduction of oxidative stress in vivo. Biol. Signals Recept. 9, 160, 2000.
35. DIETRICH K.N., WARE J.H., SALGANIK M., RADCLIFFE J., ROGAN W.J., RHOADS G.G., FAY M.E., DAVOLI C.T., DENCKLA M.B., BORNSCHEIN R.L., SCHWARZ D., DOCKERY D.W., ADUBATO S., JONES R.L. Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry. Pediatrics 114, 19, 2004.
36. CANFIELD R.L., GENDLE M.H., CORY-SLECHTA.D.A. Impaired neuropsychological functioning in lead-exposed children. Dev. Neuropsychol. 26, 513, 2004.
37. EL-SOKKARY G.H., KAMEL E.S., REITER R. Prophylactic effect of melatonin in reducing lead-induced neurotoxicity in the rat. Cell. Moll. Biol. Lett. 8, 461, 2003.
38. CHWEŁATIUK E., WŁOSTOWSKI T., KRASOWSKA A., BONDA E. The effect of orally administred melatonin on tissue accumulation and toxicity of cadmium in mice. J. Trace. Elem. Biol. Med. 19, 259, 2006.
39. LIMSON J., NYOKONG T., DAYA S. The interaction of melatonin and its precursors with aluminum, cadmium, copper, iron, lead and zinc: an adsorptive voltammetric study. J. Pineal. Res. 24, 15, 1998.
40. REITER R.J., TAN D.X., SAINZ RM, MAYO JC, LOPEZ-BURILLO S. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J. Pharm. Pharmacol. 54, 1299, 2002.
41. BODAK E., KOŁACZ R., DOBRZAŃSKI Z. Heavy metals - the conditions of exposure and the defensive mechanisms in animals. Med. Wet. 52, 619 1996. [In Polish]
42. AUNGST B.J., FUNG H.L. Kinetic characterization of in vitro lead transport across the rat small intestine. Toxicol. Appl. Pharmacol. 61, 39, 1981.
43. VARNAI V.M., SARIC M., MOKROVIC G., PIASEK M., BLANUSA M., BULJAN C.J., MATEK S.M., KOSTIAL K. The effect of dietary supplementation with calcium salts on skeletal calcium in suckling rats. Arh. Hig. Toksikol. 54, 119, 2003.
44. SILDERBERG E.K. Lead in bone: implications for toxicology during pregnancy and lactation. Environ. Health Perspect. 91, 63, 1991.
45. RABINOWITZ B.M. Toxicokinetics of bone lead. Environ. Health Perspect. 91, 33, 1991.
46. POUNDS J.G., Long G.J. Cellular and molecular toxicity of lead in bone. Environ. Health Perspect. 91, 17, 1991.
47. KOO WW, SUCCOP P.A., BORNSCHEIN R.L., KRUGWISPE SK., STEINCHEN J.J., TSANG R.C., BERGER O.G. Serum vitamin D metabolites and bone mineralization in young children with chronic low to moderate lead exposure. Pediatrics. 87, 680, 1991.
48. HEARD M., CHAMBERLAIN A. uptake of lead by human skeleton and comparative metabolism of lead and alkaline earth elements. Health Phys.47, 857, 1984.
49. DURLACH J. Magnesium in clinical practice. PZWL, Warsaw, 1991.